Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 4/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.40 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.40 |
| ▸ | COPS5 | Q92905 | 4/20 | 0.35 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.35 |
| ▸ | FBP1 | P09467 | 1/20 | 0.35 |
| ▸ | HRH2 | P25021 | 1/20 | 0.34 |
| ▸ | HRH1 | P35367 | 1/20 | 0.34 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.34 |
| ▸ | GABRP | O00591 | 1/20 | 0.34 |
| ▸ | GABRD | O14764 | 1/20 | 0.34 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.34 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.34 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.34 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27734024 | 0.86 | CYP1A2 (0.51) | CYP1A2ALDH1A1MEN1KMT2AMAPT | |
| SCHEMBL27748632 | 0.84 | CYP1A2 (0.49) | CYP1A2ALDH1A1MEN1KMT2AGABRA5 | |
| SCHEMBL1919914 | 0.80 | PTGDR2 (0.36) | CYP1A2MEN1KMT2APTGDR2 | |
| SCHEMBL1548493 | 0.79 | PTGDR2 (0.38) | CYP1A2ALDH1A1MEN1KMT2APTGDR2 | |
| SCHEMBL2175079 | 0.78 | ALDH1A1 (0.48) | CYP1A2ALDH1A1MAPTHSD17B10FBP1 | |
| SCHEMBL1417449 | 0.78 | NOS1 (0.43) | CYP1A2ALDH1A1MEN1KMT2AMAPT | |
| SCHEMBL27769969 | 0.76 | CYP1A2 (0.53) | CYP1A2ALDH1A1MEN1KMT2AMAPT | |
| SCHEMBL14058853 | 0.75 | CYP1A2 (0.37) | CYP1A2ALDH1A1MEN1KMT2AMAPT | |
| SCHEMBL28768528 | 0.75 | CYP1A2 (0.48) | CYP1A2ALDH1A1MEN1KMT2AMAPT | |
| SCHEMBL5026007 | 0.74 | CYP1A2 (0.54) | CYP1A2ALDH1A1MEN1KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0743574-B1 | Migration imaging members | XEROX CORP (US) | 2000-12-27 | — | — | EP | claimed |
| EP-0743573-B1 | Method for obtaining image contrast migration imaging members | XEROX CORP (US) | 2000-09-06 | — | — | EP | claimed |
| EP-0673784-B1 | Recording sheets containing oxazole, isooxazole, oxazolidinone, oxazoline salts, morpholine, thiazole, thiazolidine, thiadiazole, and phenothiazine compounds | XEROX CORP (US) | 1999-10-27 | — | — | EP | claimed |
| CN-102686565-B | Hepatitis c virus inhibitors | BRISTOL-MYERS SQUIBB CO. (CH) | 2015-09-30 | — | — | CN | disclosed |
| US-RE45670-E1 | Aryl carbonyl derivatives as therapeutic agents | NOVO NORDISK A/S (DK) | 2015-09-15 | — | — | US | disclosed |
| CN-102741242-B | Hepatitis c virus inhibitors | BRISTOL MYERS SQUIBB CO | 2015-07-01 | — | — | CN | disclosed |
| CN-102459250-B | Hepatitis c virus inhibitors | BRISTOL MYERS SQUIBB CO | 2015-05-06 | — | — | CN | disclosed |
| CN-102448956-B | Hepatitis c virus inhibitors | BRISTOL MYERS SQUIBB CO | 2015-05-06 | — | — | CN | disclosed |
| CN-102459281-B | Hepatitis c virus inhibitors | BRISTOL MYERS SQUIBB CO | 2015-03-11 | — | — | CN | disclosed |
| CN-102378762-B | Hepatitis c virus inhibitors | BRISTOL-MYERS SQUIBB CO. (US) | 2014-10-29 | — | — | CN | disclosed |
| CN-102227407-B | Hepatitis c virus inhibitors | BRISTOL-MYERS SQUIBB CO. (US) | 2014-10-22 | — | — | CN | disclosed |
| US-20040224996-A1 | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | BIOVITRUM AB (SE) | 2004-11-11 | — | — | US | disclosed |
| US-20040122235-A1 | Aryl carbonyl derivatives as therapeutic agents | VTV THERAPEUTICS LLC | 2004-06-24 | — | — | US | disclosed |
| WO-2004002481-A1 | ARYL CARBONYL DERIVATIVES AS THERAPEUTIC AGENTS | NOVO NORDISK A/S (DK) | 2004-01-08 | — | — | WO | disclosed |
| EP-0628038-B1 | 3-ALKYLOXY-, ARYLOXY-, OR ARYLALKYLOXYBENZO [b]THIOPHENE-2-CARBOXAMIDES AS INHIBITORS OF CELL ADHESION | WARNER LAMBERT CO (US) | 1999-08-04 | — | — | EP | disclosed |
| EP-0628038-A1 | 3-ALKYLOXY-, ARYLOXY-, OR ARYLALKYLOXYBENZO b]THIOPHENE-2-CARBOXAMIDES AS INHIBITORS OF CELL ADHESION | WARNER-LAMBERT COMPANY (US) | 1994-12-14 | — | — | EP | disclosed |
| US-5356926-A | Antiinflammatory agents | WARNER-LAMBERT COMPANY (US) | 1994-10-18 | — | — | US | disclosed |
| WO-1993017008-A1 | 3-ALKYLOXY-, ARYLOXY-, OR ARYLALKYLOXYBENZO[b]THIOPHENE-2-CARBOXAMIDES AS INHIBITORS OF CELL ADHESION | WARNER-LAMBERT COMPANY (US) | 1993-09-02 | — | — | WO | disclosed |
| US-4873253-A | Phenylalanine derivative and proteinase inhibitor | Okamoto, Shosuke (JP) | 1989-10-10 | — | — | US | disclosed |
| EP-0284632-A1 | Phenylalanine derivative and proteinase inhibitor | Okamoto, Shosuke (JP) | 1988-10-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040224996-A1 | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | HSD11B1, HSD17B1, HSD11B2 | CYP1A2 68/4885ALDH1A1 55/4885MEN1 832/4885 |
| US-20040122235-A1 | Aryl carbonyl derivatives as therapeutic agents | GCK, GCKR, PDK2 | CYP1A2 982/4885ALDH1A1 192/4885MEN1 4426/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.